Literature DB >> 7486604

Adenosine: a prototherapeutic concept in neurodegeneration.

D K von Lubitz1, M F Carter, M Beenhakker, R C Lin, K A Jacobson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7486604      PMCID： PMC3437326          DOI： 10.1111/j.1749-6632.1995.tb16573.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


× No keyword cloud information.
  108 in total

1.  Adenosine regulates via two different types of receptors, the accumulation of cyclic AMP in cultured brain cells.

Authors:  D van Calker; M Müller; B Hamprecht
Journal:  J Neurochem       Date:  1979-11       Impact factor: 5.372

2.  Changes in extracellular amino acids and spontaneous neuronal activity during ischemia and extended reflow in the CA1 of the rat hippocampus.

Authors:  P Andiné; O Orwar; I Jacobson; M Sandberg; H Hagberg
Journal:  J Neurochem       Date:  1991-07       Impact factor: 5.372

3.  Purinergic depression of neurons in different areas of the rat brain.

Authors:  G K Kostopoulos; J W Phillis
Journal:  Exp Neurol       Date:  1977-06       Impact factor: 5.330

4.  Effects of inhibitors and adenosine on (HCO3-/CO2)-stimulated swelling and Cl- uptake in brain slices and cultured astrocytes.

Authors:  R S Bourke; H K Kimelberg; M A Dazé
Journal:  Brain Res       Date:  1978-10-06       Impact factor: 3.252

5.  Endogenously released adenosine regulates excitability in the in vitro hippocampus.

Authors:  T V Dunwiddie
Journal:  Epilepsia       Date:  1980-10       Impact factor: 5.864

6.  Effect of adenosine triphosphate and some derivatives on cerebral blood flow and metabolism.

Authors:  T Forrester; A M Harper; E T MacKenzie; E M Thomson
Journal:  J Physiol       Date:  1979-11       Impact factor: 5.182

7.  Adenosine influences the high-affinity uptake of transmitter glutamate and aspartate under conditions of hepatic encephalopathy.

Authors:  W Schmidt; G Wolf; K Grüngreiff; K Linke
Journal:  Metab Brain Dis       Date:  1993-06       Impact factor: 3.584

8.  Adenosine modulates depolarization-induced release of 3H-noradrenaline from slices of rat brain neocortex.

Authors:  H H Harms; G Wardeh; A H Mulder
Journal:  Eur J Pharmacol       Date:  1978-06-01       Impact factor: 4.432

9.  Neuromodulatory actions of dopamine in the neostriatum are dependent upon the excitatory amino acid receptor subtypes activated.

Authors:  C Cepeda; N A Buchwald; M S Levine
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-15       Impact factor: 11.205

10.  Adenine nucleotides and synaptic transmission in the in vitro rat hippocampus.

Authors:  T V Dunwiddie; B J Hoffer
Journal:  Br J Pharmacol       Date:  1980-05       Impact factor: 8.739
View more
  8 in total

1.  Molecular cloning and functional characterization of inhibitor-sensitive (mENT1) and inhibitor-resistant (mENT2) equilibrative nucleoside transporters from mouse brain.

Authors:  A Kiss; K Farah; J Kim; R J Garriock; T A Drysdale; J R Hammond
Journal:  Biochem J       Date:  2000-12-01       Impact factor: 3.857

2.  Adenosine kinase is a new therapeutic target to prevent ischemic neuronal death.

Authors:  Detlev Boison; Hai-Ying Shen
Journal:  Open Drug Discov J       Date:  2010-01-01

3.  Protection against ischemic damage by adenosine amine congener, a potent and selective adenosine A1 receptor agonist.

Authors:  D K Von Lubitz; R C Lin; N Bischofberger; M Beenhakker; M Boyd; R Lipartowska; K A Jacobson
Journal:  Eur J Pharmacol       Date:  1999-03-26       Impact factor: 4.432

4.  Postischemic administration of adenosine amine congener (ADAC): analysis of recovery in gerbils.

Authors:  D K Von Lubitz; R C Lin; I A Paul; M Beenhakker; M Boyd; N Bischofberger; K A Jacobson
Journal:  Eur J Pharmacol       Date:  1996-12-05       Impact factor: 4.432

Review 5.  Modulation of apoptosis by adenosine in the central nervous system: a possible role for the A3 receptor. Pathophysiological significance and therapeutic implications for neurodegenerative disorders.

Authors:  M P Abbracchio; S Ceruti; R Brambilla; C Franceschi; W Malorni; K A Jacobson; D K von Lubitz; F Cattabeni
Journal:  Ann N Y Acad Sci       Date:  1997-10-15       Impact factor: 5.691

Review 6.  Adenosine A1 receptor agonists as clinically viable agents for treatment of ischemic brain disorders.

Authors:  N Bischofberger; K A Jacobson; D K von Lubitz
Journal:  Ann N Y Acad Sci       Date:  1997-10-15       Impact factor: 5.691

Review 7.  Adenosine receptor ligands: differences with acute versus chronic treatment.

Authors:  K A Jacobson; D K von Lubitz; J W Daly; B B Fredholm
Journal:  Trends Pharmacol Sci       Date:  1996-03       Impact factor: 14.819

8.  Reduction of postischemic brain damage and memory deficits following treatment with the selective adenosine A1 receptor agonist.

Authors:  D K Von Lubitz; M Beenhakker; R C Lin; M F Carter; I A Paul; N Bischofberger; K A Jacobson
Journal:  Eur J Pharmacol       Date:  1996-04-29       Impact factor: 4.432
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.